Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | PNMT | P11086 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | DRD3 | P35462 | 3/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5088660 | 0.82 | DRD2 (0.34) | CYP19A1CYP11B1CYP11B2MAOAMAOB | |
| SCHEMBL18845471 | 0.81 | METAP1 (0.37) | DRD2DRD3CHRM1DRD4 | |
| SCHEMBL30940171 | 0.80 | MPO (0.51) | MIF | |
| SCHEMBL19127634 | 0.80 | MPO (0.51) | MIF | |
| SCHEMBL29631990 | 0.78 | MPO (0.37) | MAOBDRD2DRD3CA1CA2 | |
| SCHEMBL20211920 | 0.78 | MPO (0.37) | MAOBDRD2DRD3CA1CA2 | |
| SCHEMBL30475404 | 0.77 | DRD2 (0.40) | MAOBDRD2DRD3CHRM1DRD4 | |
| SCHEMBL5104747 | 0.77 | DRD2 (0.40) | MAOBDRD2DRD3CHRM1DRD4 | |
| SCHEMBL5364953 | 0.76 | DRD2 (0.31) | DRD2DRD3 | |
| SCHEMBL18850177 | 0.75 | MAOB (0.44) | MAOAMAOBDRD2DRD3PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010540-B1 | SPIRO-IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2012-12-05 | — | — | EP | disclosed |
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-2010540-A1 | SPIRO-IMIDAZO COMPOUNDS | Speedel Experimenta AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007116098-A1 | SPIRO-IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192145-A1 | Spiro-Imidazo Compounds | REN, NR3C2, AGTR1 | AKR1C3 20/4885CYP19A1 104/4885BACE1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.